BDOlenic contains zoledronic acid, a potent bisphosphonate medication primarily used to manage bone-related complications in various medical conditions. It is typically administered as an intravenous infusion and works by strengthening bone and reducing the breakdown process. BDOlenic is commonly prescribed for patients with cancer that has spread to the bones, osteoporosis, and Paget’s disease of bone.

Zoledronic acid is known for its strong and sustained effect on bone resorption, helping reduce the risk of fractures and pain related to weakened or metastasised bones.

Mechanism of Action

Zoledronic acid works by targeting and inhibiting osteoclasts, the cells responsible for bone breakdown. In conditions like cancer metastasis or osteoporosis, bone resorption outpaces bone formation, leading to bone thinning or destruction.

By blocking the activity of osteoclasts, BDOlenic slows down bone loss, stabilises bone structure, and lowers the risk of skeletal complications. In cancer patients, it also helps reduce the release of calcium into the bloodstream, which can otherwise lead to serious symptoms like confusion or kidney damage.

Uses

BDOlenic is indicated for the following conditions:

• Prevention of skeletal-related events in patients with cancers that have spread to bone

• Treatment of osteoporosis, especially in postmenopausal women at high risk of fracture

• Management of hypercalcemia of malignancy, a serious condition caused by excess calcium in the blood

• Paget’s disease of bone, where bone turnover is abnormally high

• Bone loss prevention in patients receiving corticosteroids or hormone-deprivation therapy

  Adverse Effects

  BDOlenic is generally well tolerated, but some patients may experience side effects that range from mild flu-like symptoms to more specific bone-related reactions.

  Common Side Effects

  • Fever, chills, fatigue or flu-like symptoms, especially after the first infusion

  • Bone or joint pain

  • Nausea or digestive discomfort

  • Headache or general malaise